A pilot clinical study of VAL-413 (oral irinotecan HCl) in patients with recurrent pediatric solid tumors.

被引：0
|
作者：
Brown, Dennis
Bacha, Jeffrey A.
Geller, James I.
Thompson, Patrick A.
Oesterheld, Javier E.
Kanekal, Sarath
Leggas, Markos
Lopez, Lorena
Sankar, Neil
Yam, Noymi
Wagner, Lars M.
机构：
[1] Edison Oncol Holding Corp, Menlo Pk, CA USA
[2] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA
[3] Univ N Carolina, North Carolina Childrens Hosp, Chapel Hill, NC USA
[4] Levine Childrens Hosp, Carolinas Med Ctr, Charlotte, NC USA
[5] St Jude Childrens Res Hosp, Memphis, TN USA
[6] Cincinnati Childrens Hosp, Cincinnati, OH USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS10063
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A pilot clinical study of VAL-413 (Orotecan®, oral irinotecan HCl) in patients with recurrent pediatric solid tumors.
    Geller, James
    Thompson, Patrick
    Oesterheld, Javier
    Brown, Dennis M.
    Bacha, Jeffrey
    Kanekal, Sarath
    Lopez, Lorena
    Leggas, Markos
    Sankar, Neil
    Yam, Noymi
    Wagner, Lars M.
    CANCER RESEARCH, 2022, 82 (12)
  • [2] A pilot clinical study of oral irinotecan HCl (VAL-413) in patients with recurrent pediatric solid tumors
    Bacha, Jeffrey A.
    Brown, Dennis
    Geller, James I.
    Oesterheld, Javier E.
    McManus, Meghann
    Kanekal, Sarath
    Leggas, Markos
    Lopez, Lorena
    Sankar, Neil
    Yam, Noymi
    Wagner, Lars M.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [3] A pilot clinical study of orotecan (oral irinotecan HCl, VAL-413) in patients with recurrent pediatric solid tumors
    Bacha, Jeffrey
    Brown, Dennis
    Kanekal, Sarath
    Sankar, Neil
    Lopez, Lorena
    Yam, Noymi
    Wagner, Lars
    Geller, James
    Leggas, Markos
    Thompson, Patrick
    Osterheld, Javier
    CANCER RESEARCH, 2023, 83 (08)
  • [4] A multicenter phase 1-2a clinical study of Orotecan (oral irinotecan HCl, VAL-413) in patients with recurrent pediatric solid tumors
    Geller, James
    Thompson, Patrick
    Oesterheld, Javier
    Kim, Aerang
    McManus, Meghann
    Bacha, Jeffrey
    Brown, Dennis M.
    Leggas, Markos
    Kanekal, Sarath
    Sankar, Neil
    Lopez, Lorena
    Yam, Noymi
    Wagner, Lars M.
    CANCER RESEARCH, 2024, 84 (07)
  • [5] A PILOT CLINICAL TRIAL OF OROTECAN (VAL-413), A NOVEL ORAL DOSAGE FORMULATION OF IRINOTECAN: IMPLICATIONS FOR PEDIATRIC BRAIN TUMORS
    Brown, Dennis
    Bacha, Jeffrey
    Wagner, Lars
    Leggas, Markos
    Kanekal, Sarath
    Lopez, Lorena
    Sankar, Neil
    NEURO-ONCOLOGY, 2020, 22 : 60 - 60
  • [6] Pilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors
    Wagner, Lars
    Turpin, Brian
    Nagarajan, Rajaram
    Weiss, Brian
    Cripe, Timothy
    Geller, James
    PEDIATRIC BLOOD & CANCER, 2013, 60 (09) : 1447 - 1451
  • [7] Phase I study of regorafenib in combination with vincristine and irinotecan in pediatric patients with recurrent or refractory solid tumors.
    Casanova, Michela
    Bautista, Francisco
    Hewson, Quentin Campbell
    Makin, Guy
    Marshall, Lynley V.
    Verschuur, Arnauld
    Canete, Adela
    Corradini, Nadege
    Ploeger, Bart
    Mueller, Udo
    Zebger-Gong, Hong
    Chung, John Woojune
    Geoerger, Birgit
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [8] Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors.
    Meany, Holly Jane
    Dome, Jeffrey
    Hinds, Pamela S.
    Bagatell, Rochelle
    Shusterman, Suzanne
    Widemann, Brigitte C.
    Stern, Emily
    London, Wendy B.
    Kim, AeRang
    Fox, Elizabeth
    Rodriguez-Galindo, Carlos
    Minturn, Jane E.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [9] A phase I study of gefitinib and irinotecan (IRN) in pediatric patients with refractory solid tumors.
    Furman, WL
    Daw, NC
    Crews, KR
    Stewart, CF
    McCarville, B
    Santana, VM
    Hawkins, D
    Rodriguez-Galindo, C
    Navid, F
    Houghton, PJ
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 804S - 804S
  • [10] Phase I Study of Bevacizumab Plus Irinotecan in Pediatric Patients with Recurrent/Refractory Solid Tumors
    Okada, Keiko
    Yamasaki, Kai
    Tanaka, Chika
    Fujisaki, Hiroyuki
    Osugi, Yuko
    Hara, Junichi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2013, 43 (11) : 1073 - 1079
12345